Evidence map›Paper›PMID 38683564›Full record

ArticleInvestigative ophthalmology & visual science2024

CFH Haploinsufficiency and Complement Alterations in Early-Onset Macular Degeneration.

Rayne R Lim, Sharlene Shirali, Jessica Rowlan, Abbi L Engel, Marcos Nazario, Kelie Gonzalez, Aspen Tong, Jay Neitz, Maureen Neitz, Jennifer R Chao

Open access · goldAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Evidence for the Pathogenicity of aMedicina (Kaunas, Lithuania) · 2025
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Rayne R LimDepartment of Ophthalmology, University of Washington, Seattle, Washington, United States.
Sharlene ShiraliDepartment of Ophthalmology, University of Washington, Seattle, Washington, United States.
Jessica RowlanDepartment of Ophthalmology, University of Washington, Seattle, Washington, United States.
Abbi L EngelCenter for Developmental Biology and Regenerative Medicine, Seattle Children's Institute, Seattle, Washington, United States.
Marcos NazarioDepartment of Ophthalmology, University of Washington, Seattle, Washington, United States.
Kelie GonzalezDepartment of Ophthalmology, University of Washington, Seattle, Washington, United States.
Aspen TongDepartment of Ophthalmology, University of Washington, Seattle, Washington, United States.
Jay NeitzDepartment of Ophthalmology, University of Washington, Seattle, Washington, United States.
Maureen NeitzDepartment of Ophthalmology, University of Washington, Seattle, Washington, United States.
Jennifer R ChaoDepartment of Ophthalmology, University of Washington, Seattle, Washington, United States.
University of Washington · USSeattle Children's Hospital · US

Funding

Vision Research CoreP30EY001730 · NEI · UNIVERSITY OF WASHINGTON · PI JAMES Bryant HURLEY · 1985 to 2026
$23.5M
Metabolic dysfunction from ECM remodeling in diseases of human RPER01EY034364 · NEI · UNIVERSITY OF WASHINGTON · PI Jennifer Rayming Chao, Jianhai Du · 2022 to 2026
$2.8M
Metabolism of AMD iPSC-derived RPEU01EY034591 · NEI · UNIVERSITY OF WASHINGTON · PI CHAO, JENNIFER RAYMING, DU, JIANHAI · 2022 to 2024
$1.3M
NEI NIH HHS P30 EY001730NEI NIH HHS R01 EY034364NEI NIH HHS U01 EY034591
6 · The paper itself

Abstract

Purpose: Complement dysregulation is a key component in the pathogenesis of age-related macular degeneration (AMD) and related diseases such as early-onset macular drusen (EOMD). Although genetic variants of complement factor H (CFH) are associated with AMD risk, the impact of CFH and factor H-like protein 1 (FHL-1) expression on local complement activity in human retinal pigment epithelium (RPE) remains unclear. Methods: We identified a novel CFH variant in a family with EOMD and generated patient induced pluripotent stem cell (iPSC)-derived RPE cells. We assessed CFH and FHL-1 co-factor activity through C3b breakdown assays and measured complement activation by immunostaining for membrane attack complex (MAC) formation. Expression of CFH, FHL-1, local alternative pathway (AP) components, and regulators of complement activation (RCA) in EOMD RPE cells was determined by quantitative PCR, western blot, and immunostaining. Isogenic EOMD (cEOMD) RPE was generated using CRISPR/Cas9 gene editing. Results: The CFH variant (c.351-2A>G) resulted in loss of CFH and FHL-1 expression and significantly reduced CFH and FHL-1 protein expression (∼50%) in EOMD iPSC RPE cells. These cells exhibited increased MAC deposition upon exposure to normal human serum. Under inflammatory or oxidative stress conditions, CFH and FHL-1 expression in EOMD RPE cells paralleled that of controls, whereas RCA expression, including MAC formation inhibitors, was elevated. CRISPR/Cas9 correction restored CFH/FHL-1 expression and mitigated alternative pathway complement activity in cEOMD RPE cells. Conclusions: Identification of a novel CFH variant in patients with EOMD resulting in reduced CFH and FHL-1 and increased local complement activity in EOMD iPSC RPE supports the involvement of CFH haploinsufficiency in EOMD pathogenesis.

Indexed as

Complement Factor HHaploinsufficiencyIntracellular Signaling Peptides and ProteinsLIM Domain ProteinsMacular DegenerationMuscle ProteinsRetinal Pigment EpitheliumBlotting, WesternComplement ActivationComplement C3b Inactivator ProteinsComplement System ProteinsFemaleHumansInduced Pluripotent Stem CellsMaleMiddle AgedCFH protein, humanComplement C3b Inactivator ProteinsComplement Factor HComplement System ProteinsFHL1 protein, humanIntracellular Signaling Peptides and ProteinsLIM Domain ProteinsMuscle Proteins

Identifiers

PMID38683564
PMCPMC11059804
OpenAlexW4396515385

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.